| Name | Title | Contact Details |
|---|
Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.
Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Empirico is a venture-backed, next-generation therapeutics company founded on utilizing huge biological data sets, human genetics and programmable biology to power novel target discovery and development.
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors.
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company`s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux` discovery and development efforts revolves around the company`s proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.